People with a rare and aggressive blood cancer will benefit from a potentially life saving treatment, following NICE’s recommendation of a CAR-T (chimeric antigen receptor T-cell) treatment developed ...

Autolus Therapeutics plc (Nasdaq: AUTL), an early commercial-stage biopharmaceutical company developing, manufacturing and delivering next-generation programmed T cell therapies, announces that the ...

Reimbursement authority NICE has ruled that London-based Autolus' Aucatzyl (obecabtagene autoleucel or obe-cel) can be used ...

Aucatzyl will be available through routine commissioning by the NHS, the company said. ・Aucatzyl was approved by the U.S.

"UK-developed leukaemia cell therapy to be offered on NHS" was originally created and published by Pharmaceutical Technology, a GlobalData owned brand.

In 1961, Jacques Miller discovered the function of the thymus, a lymphatic organ that houses important immune cells as they grow and expand. As part of his Ph.D. thesis research, Miller studied the ...

There's been a yearslong will-they or won’t-they situation between England’s cost-effectiveness watchdog and Gilead’s Kite—as well as Novartis—for their respective CAR-T therapies. Now, Gilead has ...

A price reduction has persuaded England's drugs’ spending watchdog to recommend voxelotor (Oxbryta, Pfizer) for routine NHS use in treating haemolytic anaemia caused by sickle cell disease (SCD). The ...

On the rocky road to ensuring access to gene therapy Casgevy in the U.K., Vertex and CRISPR Therapeutics are making inroads by securing a thumbs-up from England’s National Institute for Health and ...